Lower Drug Dose Spells Trouble For Pharmacogenetic Test
This article was originally published in The Gray Sheet
Executive Summary
A study published in the June 20 issue of the Journal of Clinical Oncology shows that a genetic test is unnecessary in children if the cancer drug irinotecan is given in a low dose over a period of days